Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:27:54 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:MRK - MERCK & CO INC - https://www.merck.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRK - Z1.0110.19·122.501.1121.93+2.1651.813,083.31,586,793100,244120.76  122.66  120.44122.43  73.3119:46:22Feb 0515 min RT 2¢

Recent Trades - Last 10 of 100244
Time ETExPriceChangeVolume
19:46:22Z122.602.852
19:46:18Z121.782.031
19:38:30Z122.002.254
19:32:27Z121.561.81100
19:23:08Z121.752.005
19:22:23Z121.902.152
19:22:23Z121.892.149
19:22:23Z121.902.157
19:21:38Z121.561.813
19:21:12Z121.792.0420

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 07:05U:MRKNews ReleaseMerck Announces Health Canada Approval of ENFLONSIA(TM) for the prevention of RSV in newborns and infants
2026-02-03 06:30U:MRKNews ReleaseMerck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
2026-01-27 15:07U:MRKNews ReleaseMerck Announces Second-Quarter 2026 Dividend
2026-01-20 06:00U:MRKNews ReleaseModerna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
2026-01-07 06:50U:MRKNews ReleaseMerck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
2026-01-07 06:45U:MRKNews ReleaseMerck to Complete Acquisition of Cidara Therapeutics
2026-01-07 06:30U:MRKNews ReleaseMerck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
2026-01-05 06:45U:MRKNews ReleaseMerck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 14:39U:MRKNews ReleaseMerck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
2025-12-17 06:45U:MRKNews ReleaseKEYTRUDA(TM) (pembrolizumab) Plus Padcev(TM) (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
2025-12-12 08:45U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR(TM) (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
2025-12-08 07:00U:MRKNews ReleaseSaskatchewan Adds CAPVAXIVE(TM) to Publicly Funded Adult Immunization Program
2025-12-04 12:05U:MRKNews ReleaseFDA Conditionally Approves Merck Animal Health's EXZOLT(TM) CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
2025-12-01 06:45U:MRKNews ReleaseMerck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
2025-11-26 07:15U:MRKNews ReleaseMerck to Participate in the Citi 2025 Global Healthcare Conference
2025-11-26 06:45U:MRKNews ReleaseMerck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
2025-11-24 06:45U:MRKNews ReleaseMerck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
2025-11-21 19:30U:MRKNews ReleaseMerck Recommends Rejection of Tutanota's "Mini-Tender" Offer
2025-11-21 16:12U:MRKNews ReleaseFDA Approves KEYTRUDA(TM) (pembrolizumab) and KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev(TM) (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
2025-11-20 07:00U:MRKNews ReleaseMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR(TM) (sotatercept)